Biofilm aggregates and the host airway-microbial interface

L Hall-Stoodley, KS McCoy - Frontiers in Cellular and Infection …, 2022 - frontiersin.org
Biofilms are multicellular microbial aggregates that can be associated with host mucosal
epithelia in the airway, gut, and genitourinary tract. The host environment plays a critical role …

Precision approaches to chronic obstructive pulmonary disease management

M Moll, EK Silverman - Annual Review of Medicine, 2024 - annualreviews.org
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality
worldwide. COPD heterogeneity has hampered progress in developing pharmacotherapies …

Unique and shared systemic biomarkers for emphysema in Alpha-1 Antitrypsin deficiency and chronic obstructive pulmonary disease

KA Serban, KA Pratte, C Strange, RA Sandhaus… - …, 2022 - thelancet.com
Summary Background Alpha-1 Antitrypsin (AAT) deficiency (AATD), the most common
genetic cause of emphysema presents with unexplained phenotypic heterogeneity in …

Contemporary concise review 2022: chronic obstructive pulmonary disease

PMA Calverley, PP Walker - Respirology, 2023 - Wiley Online Library
SUMMARY OF KEY POINTS International respiratory organizations now recommend using
lower limit of normal and standardized residuals to diagnose airflow obstruction and COPD …

Does chronic obstructive pulmonary disease originate from different cell types?

Y Tesfaigzi, JL Curtis, I Petrache… - American journal of …, 2023 - atsjournals.org
The onset of chronic obstructive pulmonary disease (COPD) is heterogeneous, and current
approaches to define distinct disease phenotypes are lacking. In addition to clinical …

Alpha-1 antitrypsin deficiency: current therapy and emerging targets

OF McElvaney, DD Fraughen… - Expert Review of …, 2023 - Taylor & Francis
Introduction Alpha1 antitrypsin deficiency (AATD), a common hereditary disorder affecting
mainly lungs, liver and skin has been the focus of some of the most exciting therapeutic …

Bronchoscopic lung volume reduction in patients with emphysema due to alpha-1 antitrypsin deficiency

S Everaerts, JE Hartman, M Van Dijk, TD Koster… - Respiration, 2023 - karger.com
Background: Bronchoscopic lung volume reduction using one-way endobronchial valves
(EBVs) is a valid therapy for severe emphysema patients. However, alpha-1 antitrypsin …

Connections for matters of the heart: network medicine in cardiovascular diseases

AR Sonawane, E Aikawa, M Aikawa - Frontiers in Cardiovascular …, 2022 - frontiersin.org
Cardiovascular diseases (CVD) are diverse disorders affecting the heart and vasculature in
millions of people worldwide. Like other fields, CVD research has benefitted from the deluge …

[HTML][HTML] Alpha1-antitrypsin deficiency in Greece: Focus on rare variants

SA Papiris, M Veith, AI Papaioannou, V Apollonatou… - Pulmonology, 2024 - Elsevier
Abstract Purpose A 1 Antitrypsin deficiency (AATD) pathogenic mutations are expanding
beyond the PI* Z and PI* S to a multitude of rare variants. Aim to investigate genotype and …

Testing patterns and disparities for alpha-1 antitrypsin deficiency

L Riley, A Sriram, M Brantly, J Lascano - The American Journal of Medicine, 2023 - Elsevier
Background Alpha-1 antitrypsin deficiency is an under-recognized genetic cause of chronic
lung and liver disease; it remains unclear what the testing frequency and disparities are for …